SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire &amp; inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

The 401JK community is actively rallying behind a meme-centric narrative that mocks traditional retirement systems, viewing their token as a grassroots "people's coin" alternative to corporate financial structures. Investors remain highly engaged through a mixture of IRL marketing raids, social media momentum, and a focus on long-term conviction, with many users highlighting the project's consistent growth in subreddit rankings and community-driven development despite broader market volatility.

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

The MELANIA cryptocurrency is trending as community members engage in heated debates over its status as a failed investment, with many users characterizing it as a pump-and-dump scheme linked to the Trump family. Discussions are dominated by widespread frustration over significant valuation declines and critical comparisons to other speculative assets, reflecting a deeply bearish sentiment among active retail traders.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

$AIRCOIN is rallying as the community highlights the project's unique PvE-focused narrative, significant supply lock-ups via the AirLock protocol, and a growing, transparent ecosystem. Investors are actively discussing the project's potential to reach new milestones as they leverage strong holder retention and organic treasury growth to build sustained momentum on the Solana blockchain.

BoringDAO

BoringDAO is gaining attention as The Boring Company secures major infrastructure contracts for tunnel projects in Dubai and Nashville, fueling community excitement around the firm's rapid construction capabilities. Investors are actively discussing the potential for these hyperloop systems to scale and the broader impact of integrating high-speed subterranean transport with existing urban vehicle networks.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors position themselves ahead of upcoming earnings, fueled by optimism over QNX-driven sector momentum and strategic partnerships in physical AI and automotive software. Community discussions are heavily focused on the company's long-term growth narrative and potential breakout performance as it expands its influence in the connected enterprise market.

Stratasys Ltd. engages in the development of industrial grade additive solutions. It offers three-dimensional (3D) printer and parts, materials, and software. The company was founded on March 3, 1998 and is headquartered in Eden Prairie, MN.

Stratasys Ltd

Stratasys is trending as investors digest the company's recent earnings and performance, while simultaneously speculating on its role in broader additive manufacturing consolidation. The community is actively debating potential merger scenarios involving other industry players, driven by the company's solid balance sheet and strategic position in defense and aerospace supply chains.

Inseego Corp. engages in the business of communication equipment. Its products include mobile hotspots, industrial gateways and routers, home and enterprise routers, industrial USB modems, and telematics and mobile tracking hardware devices. Its SaaS platforms include Ctrack, an asset tracking and management solution that delivers business intelligence for fleets used in various verticals, including aviation, construction, government, and transport, and Device Management Solutions, a hosted subscription management platform. The company was founded on April 26, 1996 and is headquartered in San Diego, CA.

Inseego Corp

Inseego Corp is trending as investors react to a significant acquisition of Nokia's Fixed Wireless Access business, which is expected to expand the company's global footprint and revenue base. The community is actively discussing the strategic value of this deal, the company's pivot toward high-growth 5G infrastructure, and the potential for increased institutional interest in the stock.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is seeing intense retail chatter following rumors that GameStop is building a stake in the company to pursue a potential acquisition. While the community is debating the feasibility of such a deal given the significant market capitalization gap, traders are closely tracking unusual options activity and institutional movements surrounding both stocks.

Ethereum Classic

Ethereum Classic is seeing increased chatter as investors speculate on a potential decoupling from broader market trends and anticipate a long-awaited breakout. Community sentiment remains deeply polarized between long-term holders frustrated by years of stagnation and others viewing current price levels as a tactical entry point for a future rally.

Direxion Shares ETF Trust - Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X ETF

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

GUSH is drawing significant attention from investors as geopolitical tensions and supply risks in the Middle East drive volatility in the oil and gas sector. The community is actively debating the sustainability of these price spikes, with many using the fund to hedge or capitalize on energy sector movements amidst ongoing uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of "Moderate Buy" by Brokerages

REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the ten brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight...

OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts Ahead

Ocugen faces a packed 2026-27 catalyst window with filings, interim data and Phase III readouts across three one-time retinal gene therapies.

Ocugen Stock Outlook: Valuation, Cash Runway and Dilution Risk

Ocugen offers upside from a packed 2026 catalyst calendar, but cash runway limits and dilution risk keep the pre-commercial biotech outlook finely balanced.

REGENXBIO (NASDAQ:RGNX) Shares Pass Below 200-Day Moving Average - Should You Sell?

REGENXBIO (NASDAQ:RGNX) Stock Price Crosses Below 200-Day Moving Average - Here's What Happened...

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss...

RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud...

RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27...

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against REGENXBIO Inc. (REGENXBIO or the Company) (NASDAQ: RGNX) and reminds investors of the April 14...

RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit -- The Gross Law Firm

RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit -- The Gross Law Firm RGNX Shareholder Alert: Investors With Losses May Seek to...

<ul class="summary-bullets"><li>Hemmati served as Capricor’s vice president of medical and clinical development for new therapies between 2015 and 2017.</li><li>Capricor is awaiting an FDA decision on its DMD therapy, Deramiocel, expected by Aug. 22.</li><li>The FDA resumed review last month after issuing a Complete Response Letter in July 2025, requesting additional clinical data.</li></ul>Shares of Capricor Therapeutics (CAPR) jumped 1% in premarket trading on Tuesday after reports said a former company executive is being considered to lead the FDA’s top gene therapy division just months before a key approval decision on its Duchenne muscular dystrophy (DMD) treatment.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> jumped 11% on Monday to end at $34.54, logging its best session in nearly two months.<h2 class="st-heading-2">Former Capricor Executive Emerges As FDA Biologics Chief Candidate</h2>Houman Hemmati, who served as vice president of medical and clinical development for new therapies at Capricor between 2015 and 2017, is among the candidates being interviewed by FDA Commissioner Marty Makary to head the Center for Biologics Evaluation and Research, or CBER, Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-04-13/eye-doctor-considered-for-fda-vaccine-post-is-a-fox-news-regular">reported</a>.The division oversees approvals of vaccines and advanced gene and cell therapies, including treatments for rare diseases such as DMD. However, HHS spokesperson Andrew Nixon reportedly said no selection has been finalized and that the agency is still evaluating candidates.<h2 class="st-heading-2">CAPR Awaits Key FDA Ruling On DMD Therapy</h2>The development comes as Capricor awaits an FDA decision on Deramiocel, its investigational therapy for DMD, a rare genetic condition that causes progressive muscle weakness in children, expected by Aug. 22.The FDA resumed review of Deramiocel last month after issuing a Complete Response Letter (CRL) in July 2025, which indicated earlier that the agency could not approve the drug in its current form and typically requests additional data. Capricor’s resubmission included Phase 3 Hope-3 trial results showing 54% slower deterioration in upper-limb function and 91% slowing of cardiac disease progression, both statistically significant compared with placebo.Deramiocel consists of donor-derived cardiac cells, which reduces inflammation linked to muscle degeneration in DMD.<h2 class="st-heading-2">Prasad Exit Seen As Positive For Biotech Approvals</h2>The CBER leadership opening follows the departure this month of outgoing director Vinay Prasad, whose tenure drew criticism from the biotech industry over regulatory decisions affecting rare-disease therapies.Prasad’s exit news lifted several biotech stocks last month, with BMO Capital Markets calling the change “a sigh of relief” for the sector and saying it could improve approval prospects for multiple companies developing advanced therapies.During his tenure, Prasad was involved in disputes with companies, including Sarepta Therapeutics, over gene-therapy reviews and disagreements with UniQure and Regenxbio. He also briefly stepped away from the agency last year amid political criticism over regulatory decisions before returning weeks later with Makary’s support.<h2 class="st-heading-2">How Do Retail Traders Feel About CAPR?</h2>On Stocktwits, retail sentiment for CAPR jumped to ‘bullish’ from ‘bearish’ levels over the past day amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/capr_ss_png_26c2d1b5ac.webp" alt="capr ss.png" width="963" height="149"><figcaption>CAPR sentiment and message volume as of April 14 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/graywolf/message/650157552">said</a>, “$45-50 is my guess if the appointment is confirmed. 75+ upon approval, and $100+ with sale numbers,” referring to the prospects of Hemmati leading the CBER.<stembedurl>https://stocktwits.com/graywolf/message/650157552</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/WBinthehouse/message/650152118">said</a>, “if Dr Hemmati gets appointed as CBER chief, Vinay Prasad is gonna want credit for CAPRs approval. Will beat David to the punch. Guaranteed! Lol”<stembedurl>https://stocktwits.com/WBinthehouse/message/650152118</stembedurl>CAPR stock has jumped over 270% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-killers-musk-taunts-rivals-after-q1-us-deliveries-top-ev-market/cZJpx1BRIHE">'What Happened To All The Tesla Killers?' Elon Musk Taunts Rivals As Q1 US Deliveries Beat Every Other EV Maker Combined</a>

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision

Outgoing CBER director Vinay Prasad will depart this month, boosting approval prospects for several rare-disease therapies.

Equity

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Current Price	$9.12
Prev Close	$8.97
Open	$8.97
Dividend Yield	0.00%
50-Day Moving Average	$8.76
Beta	1.66
Avg. Volume	558,611.81
PE Ratio	-2.43

52-Week High	$16.19
52-Week Low	$6.89
Market Capitalization	$470.75M
EPS (Annual)	-$3.76
Price to Book	4.52
Revenue Per Employee	$459,409.70

RGNX
Regenxbio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RGNX News

RGNXRegenxbio Inc